Non Small Cell Lung Cancer Clinical Trial
Official title:
Safety and Efficacy Phase I/IIa Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
Verified date | October 2013 |
Source | CureVac AG |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase I/IIa open, uncontrolled, international, prospective clinical trial, in an
out-patient setting, in patients with stage IIIB/IV NSCLC.
The phase I part of the study consists of a dose escalation phase, in which the recommended
dose (RD) for the phase IIa part of the study will be established based on the incidence of
dose-limiting toxicities (DLT). In the phase IIa part of the study, additional patients will
be included at the RD, to confirm the safety and explore the activity of that dose.
This study will take place in Switzerland (2 sites) and Germany (11 sites).
Status | Completed |
Enrollment | 46 |
Est. completion date | May 2014 |
Est. primary completion date | February 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Male or female and age = 18 yrs and = 75 2. Histologically or cytologically confirmed and documented stage IIIB /IV NSCLC 3. Documented stable disease or objective response according to RECIST criteria after initial chemotherapy or chemo-radiotherapy for advanced, unresectable disease: - Patients must have received a minimum of two cycles of standard chemotherapy, and adequate and effective radiotherapy if used in conjunction with chemotherapy (sequentially or concomitantly). Prophylactic brain radiation is allowed. - Surgery, radiotherapy and/ or chemotherapy can have been previously administered for non-advanced disease. - All therapies must be completed 4 weeks before start of study treatment. 4. Performance status: Eastern Cooperative Oncology Group (ECOG) 0 - 1 5. Life expectancy > 6 months as assessed by the investigator 6. Adequate organ function: - Bone marrow function: hemoglobin = 100 g/L; white blood cell count (WBC) = 3.0 x 109/L; lymphocyte count = 1.0 x 109/L; absolute neutrophil count (ANC) = 1.5 x 109/L; platelet count = 100 x 109/L - Hepatic: aspartate transaminase (AST) and alanine transaminase (ALT) = 2.5 times upper limit of normal (ULN) (= 5 x ULN if hepatic metastases present); bilirubin = 1.5 x ULN - Renal: Creatinine = 2 mg/ dL and creatinine clearance = 45 mL/ min 7. Patients of child-producing potential must agree to use contraception while enrolled in the study and for one month after the last immunization 8. Written informed consent must be obtained prior to conducting any study-specific procedures. Exclusion Criteria: 1. History of anti-cancer therapy for advanced disease other than initial chemotherapy or chemo-radiotherapy or surgery 2. Immunotherapy within 4 weeks prior to study enrollment, including cytokines such as G-CSF, GM-CSF or interferons 3. Treatment with investigational anti-cancer agents during initial therapy for advanced disease or any investigational agents within 4 weeks prior to study enrollment 4. Concurrent anti-tumor therapy or concurrent immunotherapy such as lectins, unspecific immunostimulants, etc. 5. Previous anti-cancer immunotherapy comprising RNA-transfected dendritic cells or DNA vaccines targeting any tumor-associated antigens 6. Concurrent systemic steroids except topical (inhaled, topical, nasal) for the last 28 days, except replacement therapy 7. Concurrent major surgery or planned surgery 8. Prior splenectomy 9. Documented history of active autoimmune disorders requiring systemic immunosuppressive therapy, (e.g., sarcoidosis, lupus erythematosus, rheumatoid arthritis, glomerulonephritis or systemic vasculitis), excepting autoimmune thyroiditis with only thyroid hormone replacement and stable disease > 1 year 10. Primary or secondary immune deficiency 11. Active allergy requiring continuous medication or active infections requiring anti-infectious therapy 12. Seropositive for HIV, HBV or HCV 13. History of other malignancies over the last 5 years (except basal cell carcinoma of the skin or carcinoma in situ of the cervix) 14. Uncontrolled medical condition considered as high risk for the treatment with an investigational drug including unstable diabetes mellitus, vena-cava-syndrome, known ascites and/or uncontrolled pleural effusion. 15. Brain metastases (symptomatic or asymptomatic) or leptomeningeal involvement 16. Symptomatic congestive heart failure (NYHA 3 and 4); unstable angina pectoris within 6 months prior to enrollment; significant cardiac arrhythmia, history of stroke or transient ischemic attack 17. History of seizures, encephalitis or multiple sclerosis 18. Gastric ulcer or inflammatory bowel disease or Crohn's disease or ulcerative colitis; no active diverticulitis 19. Active drug abuse or chronic alcoholism 20. Patients being committed to an institution by virtue of an order issued either by the judicial or the administrative authorities |
Country | Name | City | State |
---|---|---|---|
Germany | RWTH Aachen | Aachen | |
Germany | Medizinische Klinik III, Universitätsklinikum Bonn | Bonn | |
Germany | Medizinische Klinik V, Klinikum Darmstadt | Darmstadt | |
Germany | Medizinische Klinik I, Universitätsklinikum Dresden | Dresden | |
Germany | Nordwest Krankenhaus | Frankfurt | |
Germany | Krankenhaus Großhansdorf | Großhansdorf | |
Germany | Universitätsklinikum Hamburg Eppendorf, Medizinische Klinik II | Hamburg | |
Germany | Thoraxklinik am Universitätsklinikum Heidelberg | Heidelberg | |
Germany | Universitätsklinikum des Saarlandes | Homburg | |
Germany | III. Medizinische Klinik und Poliklinik, Universitätsmedizin Mainz | Mainz | |
Germany | III. Medizinische Klinik, Klinikum rechts der Isar | München | |
Germany | Medizinische Klinik II, Universität Tübingen | Tübingen | |
Switzerland | UniversitätsSpital Basel | Basel | |
Switzerland | UniversitätsSpital Zürich | Zürich |
Lead Sponsor | Collaborator |
---|---|
CureVac AG |
Germany, Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Phase I: Determination of the recommended dose (RD) for exploration in the phase IIa part of the study | During the first 2-3 month of Phase I | ||
Primary | Phase II: Assessment of safety and tolerability of the treatment regimen | Complete duration of Phase II |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Completed |
NCT01945021 -
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
|
Phase 2 | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
Recruiting |
NCT05898763 -
TEIPP Immunotherapy in Patients With NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05532696 -
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04311034 -
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00349089 -
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
|
Phase 2 | |
Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04571632 -
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
|
Phase 2 | |
Terminated |
NCT03599518 -
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06020989 -
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
|
Phase 2 | |
Withdrawn |
NCT03982134 -
PDR001 + Panobinostat for Melanoma and NSCLC
|
Phase 1 | |
Withdrawn |
NCT03574649 -
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT02844140 -
DE-CT in Lung Cancer Proton Therapy
|
N/A | |
Completed |
NCT03780010 -
Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC
|
Phase 1 |